Diseño, síntesis y evaluación farmacológica de nuevos fármacos multidiana para el tratamiento de la enfermedad de Alzheimer
Alzheimer’s disease (AD) is a neurodegenerative disorder that constitutes the main form of dementia. Until recently, available treatments for AD only led to symptomatic relief, without affecting the underlying biology of the disease. Recently approved disease-modifying therapies based on monoclonal...
| Autor: | |
|---|---|
| Tipo de recurso: | tesis doctoral |
| Fecha de publicación: | 2024 |
| País: | España |
| Institución: | Universidad Complutense de Madrid (UCM) |
| Repositorio: | Docta Complutense |
| Idioma: | inglés |
| OAI Identifier: | oai:docta.ucm.es:20.500.14352/107516 |
| Acceso en línea: | https://hdl.handle.net/20.500.14352/107516 |
| Access Level: | acceso abierto |
| Palabra clave: | 616.894-053.9(043.2) Enfermedad de Alzheimer Alzheimer's disease Neurociencias (Farmacia) 2490 Neurociencias |
| Sumario: | Alzheimer’s disease (AD) is a neurodegenerative disorder that constitutes the main form of dementia. Until recently, available treatments for AD only led to symptomatic relief, without affecting the underlying biology of the disease. Recently approved disease-modifying therapies based on monoclonal antibodies against β-amyloid (Aβ), despite being a breakthrough in the field, have limited clinical effect, high costs and associated side effects. Consequently, the pursuit of innovative and effective AD therapies stands as one of the mainscientific challenges in this era. AD is a multifactorial disease, characterized by a complex interplay of pathological events. Besides Aβ-containing extracellular amyloid plaques, tau-containing intracellular neurofibrillary tangles and cholinergic dysfunction, classical hallmarks of AD, other pathological processes including neuroinflammation, oxidative stress, mitochondrial dysfunction and proteostasis regulation impairment also contribute to the pathogenesis of AD... |
|---|